Media coverage of Ghislaine Maxwell’s trial ignores her family’s ties to Israeli intelligence. Part 1 traces her father Robert Maxwell, from media mogul to Mossad asset who sold the bugged PROMIS software worldwide, and the legacy of espionage three of his daughters inherited.
Los gobiernos y el FEM prometen consultar a la “sociedad civil”. Iain Davis rastrea la idea hasta el comunitarismo de Amitai Etzioni y muestra cómo la asociación público-privada global elige a esos grupos para “aprobar” decisiones ya tomadas.
Governments and the WEF now pledge to consult “civil society”. Iain Davis traces the idea to Amitai Etzioni’s communitarianism and shows how the global public-private partnership hand-picks these groups to rubber-stamp decisions already made.
The AFT and NEA say they back Biden’s school vaccine mandates on health grounds. However, both unions have spent decades partnering with IBM, Microsoft, Google and Gates and these mandates open the door to blockchain vaccine passports and digital IDs for students.
COVID-19 erased the regulatory and trial-related hurdles that Moderna could never surmount before. Yet, how did Moderna know that COVID-19 would create those conditions months before anyone else?
Whitney joined TLAV to discuss the never-ending “booster” cycle of COVID-19 injections that is already under way, and her recent article about Moderna’s mRNA shots and the miraculous timing of their “success”.
El COVID-19 eliminó las barreras regulatorias relacionadas con los ensayos clínicos que Moderna nunca pudo superar. ¿Cómo se enteró Moderna meses antes que todos que el COVID-19 crearía esas condiciones?
Antes de la COVID-19, Moderna parecía como otra Theranos: secretismo, fuga de directivos, ningún producto en nueve años, una disputa de patentes y una toxicidad que la obligó a abandonar los fármacos de dosis múltiples. La Parte 1 muestra lo cerca que estuvo del colapso, y por qué importa hoy.
Before COVID-19, Moderna looked like another Theranos: secretive, losing top staff, no product after nine years, a patent fight over its delivery system and toxicity so severe it dropped all multi-dose drugs. Part 1 shows how close it was to collapse, and why that matters for boosters.
